Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 13/20 | 0.54 |
| ▸ | CA1 | P00915 | 13/20 | 0.54 |
| ▸ | CA2 | P00918 | 13/20 | 0.54 |
| ▸ | CA4 | P22748 | 13/20 | 0.54 |
| ▸ | CA7 | P43166 | 13/20 | 0.54 |
| ▸ | CA9 | Q16790 | 13/20 | 0.54 |
| ▸ | DPP4 | P27487 | 1/20 | 0.51 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.51 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.51 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.51 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.45 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.45 |
| ▸ | HMOX1 | P09601 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL589488 | 1.00 | CA12 (0.54) | CA12CA1CA2CA4CA7 | |
| Trifluoroacetic Acid SCHEMBL2889124 | 0.94 | DPP4 (0.48) | CA12CA1CA2CA4CA7 | |
| Trifluoroacetic Acid SCHEMBL2887068 | 0.89 | LMNA (0.45) | CA12CA1CA2CA4CA7 | |
| Trifluoroacetic Acid SCHEMBL2891601 | 0.89 | LMNA (0.45) | CA12CA1CA2CA4CA7 | |
| Trifluoroacetic Acid SCHEMBL3144597 | 0.88 | CA12 (0.54) | CA12CA1CA2CA4CA7 | |
| Trifluoroacetic Acid SCHEMBL589490 | 0.88 | CA12 (0.54) | CA12CA1CA2CA4CA7 | |
| SCHEMBL3156627 | 0.86 | ALDH1A1 (0.54) | CA12CA1CA2CA4CA7 | |
| Hydrochloric Acid SCHEMBL2891558 | 0.85 | ALDH1A1 (0.53) | CA12CA1CA2CA4CA7 | |
| Trifluoroacetic Acid SCHEMBL3149597 | 0.84 | DRD2 (0.48) | CA12CA1CA2CA4CA7 | |
| SCHEMBL3144590 | 0.83 | CA12 (0.54) | CA12CA1CA2CA4CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1805181-B1 | PURINE DERIVATIVES FOR USE AS ADENOSIN A-2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2012-08-29 | — | — | EP | disclosed |
| EP-2012759-B1 | PURINE DERIVATIVES AS A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2010-03-10 | — | — | EP | disclosed |
| US-20090093633-A1 | Organic Compounds | NOVARTIS AG | 2009-04-09 | — | — | US | disclosed |
| EP-1841768-B1 | PURINE DERIVATIVES ACTING AS A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2008-11-12 | — | — | EP | disclosed |
| US-20080207648-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-08-28 | — | — | US | disclosed |
| US-20080200483-A1 | Purine Derivatives for Use as Adenosin A-2A Receptor Agonists | NOVARTIS AG (CH) | 2008-08-21 | — | — | US | disclosed |
| EP-1841768-A1 | PURINE DERIVATIVES ACTING AS A2A RECEPTOR AGONISTS | Novartis AG (CH) | 2007-10-10 | — | — | EP | disclosed |
| WO-2006074925-A1 | PURINE DERIVATIVES ACTING AS A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093633-A1 | Organic Compounds | ADORA2A, ADORA3, ADORA1 | CA12 2195/4885CA1 1723/4885CA2 1325/4885 |
| US-20080200483-A1 | Purine Derivatives for Use as Adenosin A-2A Receptor Agonists | ADORA2A, ADORA1, ADORA3 | CA12 4138/4885CA1 4030/4885CA2 1804/4885 |
| US-20080207648-A1 | Organic Compounds | ADORA2A, ADORA1, ADORA3 | CA12 1617/4885CA1 1669/4885CA2 593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.